Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

Status Active, not recruiting

Clinical Trial Summary

Clinical Trial Description

This is a randomized, multicenter phase II study of pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma as assessed by 1 year disease free survival rate. The investigators primary aim is to examine the safety and efficacy of pembrolizumab in both pre-operative treatment paradigms for esophageal/GEJ carcinoma. The specific rationale for the investigators study design is rooted in three unanswered questions: 1. does the addition of an immune check-point inhibitor (pembrolizumab) enhance the efficacy of cytotoxic therapy (chemotherapy with chemoradiation) as determined by response rates, nodal down-staging and 1 year disease free survival in comparison to historical controls, 2. what are the pathological effects of combining pembrolizumab with chemotherapy alone, and 3. what are the molecular (PD-L1 expression), immunological (TILs extent) and gene-expression signatures associated with the efficacy of pembrolizumab in the neoadjuvant setting. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02998268
Study type	Interventional
Source	Weill Medical College of Cornell University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 7, 2017
Completion date	September 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04159974` - RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus	Phase 2
Completed	`NCT03015389` - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Terminated	`NCT04642690` - Nitrates and IL-8 in Barrett's Esophagus
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Completed	`NCT02128243` - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Phase 2
Recruiting	`NCT04430738` - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers	Phase 1/Phase 2
Recruiting	`NCT04114136` - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies	Phase 2
Terminated	`NCT03223662` - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy	Phase 2
Recruiting	`NCT05530343` - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance	N/A
Active, not recruiting	`NCT03539822` - Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies	Phase 1/Phase 2
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT01970306` - Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material	Phase 2
Recruiting	`NCT06071845` - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples	N/A
Active, not recruiting	`NCT02872116` - Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	Phase 3
Terminated	`NCT04089904` - Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma	Phase 2
Recruiting	`NCT05177133` - Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)	Phase 2
Recruiting	`NCT02962063` - Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer	Phase 1/Phase 2
Recruiting	`NCT02606396` - Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer	N/A
Completed	`NCT02610764` - Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC	N/A
Terminated	`NCT00430027` - Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma	N/A